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Expression of HLA-G in Human Cornea, an
Immune-Privileged Tissue
Magali Le Discorde, Philippe Moreau, Patrick Sabatier,
Jean-Marc Legeais, and Edgardo D. Carosella
ABSTRACT: Human leukocyte antigen (HLA)-G retains
the capacity to modulate immune responses, favoring the
establishment of tolerance in solid-tissue allotransplants.
To better understand the mechanisms that promote cor-
neal allograft survival, we investigated whether HLA-G
was an immunoregulatory factor involved in corneal im-
munology. We therefore sought HLA-G expression in
corneal tissues. Corneal transplantation consists in replac-
ing the center of a diseased cornea with normal corneal
tissue. Two corneal parts are not used in such surgery:
diseased central corneal tissue and peripheral normal cor-
nea. For this study, we used healthy corneas obtained from
deceased donors and diseased corneas obtained from pa-
tients with pseudophakic bullous keratopathy or kerato-
conus who had undergone corneal transplantation. Immu-
nohistochemical analysis carried out on the cryopreserved
corneas showed a positive immunohistochemical staining
with anti–HLA-G, anti–HLA-A, -B, and -C, and anti–
HLA class I monoclonal antibodies. Staining was obtained
for keratocytes, epithelial cells, and endothelial cells from
both healthy and pathologic human corneas, revealing the
presence of HLA class I proteins, including HLA-G.
HLA-G transcripts were detected in normal cornea by
reverse transcriptase–polymerase chain reaction with a
classical pattern of alternative splicing. The detection of
HLA-G protein in adult corneas leads to the conclusion
that this protein may contribute to the maintenance of the
privileged immune status of cornea. Human Immunology
64, 1039–1044 (2003). © American Society for Histo-
compatibility and Immunogenetics, 2003. Published by
Elsevier Inc.
KEYWORDS: HLA; cornea; keratoplasty; immunohis-
tochemistry; RT-PCR
ABBREVIATIONS
HLA human leukocyte antigen
RT-PCR reverse transcription-polymerase chain
reaction
OCT optimal cutting temperature compound
INTRODUCTION
In the normal immune system, activated immune cells
attack invading organisms to protect the body from
infection and disease. However, this normal immune
mechanism induces inflammatory reactions, which, mi-
nor as they may be, could damage tissues beyond repair.
Thus, inflammation resulting from a normal immune
response could damage the cornea, leading to impaired
vision or even blindness [1]. To prevent these tissue-
damaging reactions, the immune response in cornea and
others areas of the body is blocked by mechanisms in-
trinsic to the tissue concerned. These particular organs,
which are considered to be immune-privileged sites,
include ovary, testis, brain, and eye. The immunologic
status of these organs could be compared with what
occurs at the maternal-fetal interface during pregnancy,
where immune tolerance is observed, avoiding rejection
of the semiallogenic fetus [2]. Among the various mech-
anisms activated in trophoblast cells to establish this
immune protection, nonclassical class I human leukocyte
antigen (HLA) proteins play an active immunologic role
[3]. HLA-G presents low polymorphism, with 15 allelic
variations providing 7 different HLA-G1 proteins [4, 5].
At the transcriptional level, the primary HLA-G tran-
script undergoes alternative splicing, resulting in four
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membrane-bound (HLA-G1 through -G4) and three sol-
uble (HLA-G5 through G7) isoforms, among which only
HLA-G1 and HLA-G5 contain all the domains of clas-
sical HLA molecules (1, 2, and 3) noncovalently
associated with 2-microglobulin and a nonameric pep-
tide.
Expression of HLA-G antigens allows cells to escape
immunosurveillance. Indeed, several studies have con-
firmed that HLA-G expression, either at the cell mem-
brane or by secretion of the soluble form, inhibits the
lytic activity of both natural killer and antigen-specific
cytotoxic T-cell effectors [6–8]. HLA-G may regulate
the proinflammatory Th1/anti-inflammatory Th2 cyto-
kine balance by shifting toward Th2 polarization [9].
Considering that HLA-G contribute to the escape of the
fetus from immunologic attack by specialized maternal
immune cells and the similar immune-privileged status
of cornea, we hypothesized that HLA-G could be ex-
pressed in human cornea and thus contribute to the
specific immune control of that tissue. The aim of this
work was therefore to determine whether HLA-G protein
could be detected in healthy and pathologic corneas. The
two pathologies we studied are among the most common
corneal diseases treated by corneal transplantation: one
inflammatory (pseudophakic bullous keratopathy) and
one degenerative (keratoconus). The normal human cor-
nea we studied was obtained from postmortem donors,
and the pathologic corneas came from patients present-
ing pseudophakic bullous keratopathy and keratoconus.
Our results are the first demonstration that normal hu-
man cornea, an immune-privileged tissue, expresses the
immunoregulatory molecule HLA-G, and that this ex-
pression is apparently unaltered in corneas affected in
both tested pathologies: the pseudophakic bullous kera-
topathy, which is an inflammatory condition of the cor-
nea, and the keratoconus, a degenerative disease.
MATERIALS AND METHODS
Human Tissues
Corneal transplant surgery involves total replacement of
a patient’s cornea with a donor cornea. In corneal trans-
plantation, a round section of cornea from the donor is
sewed in place of the diseased cornea. We used the
peripheral part of the donor cornea, which is not grafted,
as the normal control, and pathologic corneal tissues
removed from diseased central corneas as pathologic tis-
sue samples.
Ten normal human corneas were obtained from post-
mortem donors, and 11 pathologic corneas were obtained
from patients presenting pseudophakic bullous keratopa-
thy (n  5) or keratoconus (n  6), the two most
common diseases for which corneal transplantation is
needed [10].
Antibodies
All HLA-G isoforms were labeled using the 4H84 mono-
clonal antibody, an immunoglobulin (Ig)G1 antidena-
tured HLA-G heavy chain targeting an epitope located
on the 1-domain (S. Fisher and M. McMaster); the
IgG2a pan-class I monoclonal antibody W6/32, which
recognizes classical or nonclassical HLA class I associated
with 2-microglogulin; the monoclonal antibody
SV99-85 (S. Ferrone), and an IgG exhibiting a restricted
label to classical HLA-A, -B and -C. Incubation with
isotypic control IgG1 or IgG2a was used as the negative
control.
Immunohistochemistry
Human corneas were encapsulated by optimal clotting
temperature (OCT) compound and frozen in 5-m-thick
sections, fixed in acetone, and stored at 80 °C until
immunohistochemical analysis.
Expression of HLA-G and HLA class I protein were
evaluated on acetone-fixed cryosections, using the Ultra-
Tech HRP Streptavidin-Biotin Universal Detection Sys-
tem (Immunotech, Coulter, France), according to the
manufacturer’s recommendations. Briefly, rehydration,
washes, and antibody dilutions were done in PBSA (sa-
ponin 0.1%, HEPES 0.01M in phosphate buffer saline).
After endogenous peroxidase activity blockade, primary
antibodies were added for 1 hour. Peroxidase-labeled
antimouse secondary antibody was applied and revealed
by the substrate-chromogen solution 3-amino-9-ethyl-
carbazole (AEC). Tissues were counterstained with he-
matoxylin. Immunohistochemistry was carried out on 10
peripheral corneas, 5 pseudophakic bullous keratopa-
thies, and 6 keratoconus corneas.
RNA Extraction and RT-PCR
Total RNA was extracted from cornea biopsies, using
RNA-NOW reagent (Biogentex Inc., Seabrook, TX,
USA), according to the manufacturer’s recommenda-
tions. RNA was treated with RNase-free DNase (Boe-
hringer-Mannheim, Meylan, France) to remove con-
taminating chromosomal DNA. cDNA synthesis was
accomplished by reverse transcription (RT) using oli-
go(dT) primer and M-MLV RT (Gibco-BRL, Life Tech-
nologies, Cergy Pontoise, France). The polymerase
chain reaction (PCR) was run for 40 cycles at 94°C for
1 minute, at 57°C (-actin) or 61°C (HLA-G) for 1
minute, and at 72°C for 1 minute. The PCR product
was run on a 1.5% agarose electrophoresis gel and
transferred. Specificity of amplification was confirmed
by subsequent hybridization with a 32P-labeled inter-
nal probe for 2 hour at 57°C (-actin) or at 60°C
(HLA-G(R)). RT-PCR were carried out using JEG-3
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choriocarcinoma cells as the positive control, revealing
a classical HLA-G mRNA profile expression.
Oligonucleotides
HLA-G was amplified from exon 2 by G257 forward (5-
GGAAGAGGAGACACGGAACA) up to exon 5 by
G1004 reverse (5-CCTTTTCAATCTGAGCTCTTCT
TT) primers (ESGS-Groupe Cybergene, Evry, France), and
hybridization were achieved with an internal probe located
in exon 2 G(R) (5-GGTCTGCAGGTTCATTCTGTC);
-actin transcripts were detected using a forward (5-
ATCTGGCACCACACCTTCTACAATGAGCTGCG), a
reverse(5-CGTCATACTCCTGCTTGCTGATCCACAT-
CTGC) primers and an internal -actin probe (5-AT-
CATGTTTGAGACCTTCAACACCCCAGCC).
FIGURE 1 Detection of tissue antigens in normal corneas
(first column), in pseudophakic bullous keratopathy (second
column), and in keratoconus (third column). (A, B, C) Immu-
nostaining with an irrelevant antibody as negative control
immunoglobulin G1, (D, E, F) an anti–human leukocyte
antigen (HLA) class I (W6/32), (G, H, I) an anti–HLA-A, -B,
and -C antibody (SV99-85), and (J through O) an anti–HLA-G
(4H84) antibody. Positive staining for HLA class I, including
HLA-G, is revealed (D through O) in epithelial cells, stroma,
and (M, N, O) endothelial cells. 400.
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RESULTS
The cornea is a transparent membrane located at the
most anterior portion of the eye. It is organized into
three cell layers: epithelium, stroma, and endothelium.
HLA-G transcripts and protein expression were found in
all cell layers of normal and pathologic corneas studied.
Classical and Nonclassical HLA-Class I Protein
Expression in Cornea
Normal and pseudophakic bullous keratopathy and ker-
atoconus corneas were indirectly stained to target all
HLA class I antigens, classical HLA-A, -B, and -C, and
nonclassical HLA-G molecules (Figure 1, J–O). Class I
antigens were detected at a high level in frozen sections
from both healthy and pathologic corneas by the W6/32
antibody (Figure 1, D–F) in all cellular structures of the
cornea: epithelium, keratocytes from the stromal layer,
and endothelium. A similar pattern was observed with
immunostaining of the classical class I HLA-A, -B,
and-C antigens (SV99-85 antibody) (Figure 1, G–I).
HLA-G (4H84 antibody) was detected in the epithelial
layer, in keratocytes from the stroma (Figure 1, J–L), and
in endothelium (Figure 1, M–O) from normal, pseu-
dophakic bullous keratopathy, and keratoconus corneas.
This staining was confirmed with the monoclonal anti-
body MEM-G/2 (Exbio, Prague, Czech Republic), an
other anti–HLA-G proteins (data not shown).
Detection of HLA-G Transcripts in Cornea
To determine whether the HLA-G expression revealed by
immunohistochemistry could derive from different iso-
forms, we used RT-PCR to analyze which transcripts
(HLA-G1 through -G7) were expressed in normal cor-
nea. The elastic consistency of cornea tissue rendered
RNA extraction difficult. We observed the same classical
pattern of HLA-G gene expression in four successive
RT-PCRs, showing membranar HLA-G1 to HLA-G4,
and soluble HLA-G5 transcripts (Figure 2).
DISCUSSION
In this work, we have shown that the HLA-G molecule
is highly expressed in human cornea. Originally detected
in chorionic cytotrophoblast cell membranes, the
HLA-G molecule is expressed at the maternal-fetal in-
terface and is involved in the protection of fetal tissues
from maternal cellular immune attacks. After the immu-
noprotective power of HLA-G had been demonstrated
[11], research focused on its role in various cell mecha-
nisms that allow cells to escape immune surveillance,
such as fetal cells escaping maternal immunity, tumor
proliferation, and tolerance of transplanted organs by the
host immune system.
However, few investigators analyzed HLA-G expres-
FIGURE 2 Reverse transcriptase–polymerase chain reaction
(PCR) analysis of human leukocyte antigen (HLA)-G tran-
scripts in four normal corneas (A) and in the choriocarcinoma
cell line JEG-3 (B). PCR amplification was carried out using
G257-G1004 primers, respectively, in exon 2 and exons 5/6.
All HLA-G products are detected using the HLAG(R) probe
located in exon 2. Membranar isoforms (HLA-G1 to -G4) and
soluble (HLA-G5) are visualized with the same profile than in
JEG-3 cells.
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sion in other immunologically privileged tissues, such as
cornea. The immune-privileged status of organs was
usually only discussed in the context of the potential of
cells to use natural mechanisms to induce cell death
through overexpression of the apoptotic Fas ligand [12,
13]. Present knowledge of the properties of the HLA-G
molecule led us to investigate their involvement in tis-
sues of specific immune status, in which the actions of
classical immune cells are blocked to maintain the func-
tional and structural integrity of an organ, such as in the
cornea. HLA-G cDNA from a fetal human eye cDNA
library suggested that HLA-G was expressed in eye tissue
[14], but few articles have addressed the interesting
questions raised by HLA-G expression in eye tissue. A
first study, which separately investigated the anterior
and posterior parts of the eye, successfully used RT-PCR
to detect HLA-G transcripts in the anterior portion [15].
In addition, HLA-G protein expression has never been
detected in sections of any embryonic tissues, but in
1994, a single experiment was carried out in which the
antibodies used were probably not specific enough [16].
To date, only one study, using nonradioactive RT-PCR,
has reported HLA-G expression in isolated human cornea
at the transcriptional level, and other authors did not
report such detection [17]. Publications on ocular tu-
mors have reported negative expression of HLA-G in the
Y79 retinoblastoma cell line [18], in various uveal mel-
anoma cell lines, and in biopsies from primary uveal
melanomas [19]. The interpretation of results in cell
culture lines must be taken with reserve, because they
cannot always be correlated with results obtained with
the identical primary tumor. Indeed, cell-line culture
media may be deficient in factors implicated in the
maintenance of HLA-G expression that are often secreted
by malignant cells, such as interleukin-10, which in-
duces HLA-G cell-surface expression but is not found in
excised tumor tissue [20–22]. In addition, induction of
HLA-G protein expression after cytokine treatment of
cell lines argues in favor of this point of view [23]. The
absence of HLA-G protein in primary uveal melanomas
was not surprising, because HLA-G has not been sys-
tematically described in melanomas [24]. Until now,
HLA-G protein expression has been described as ex-
tremely restricted to fetal tissues (cytotrophoblasts, am-
nion epithelial cells, and chorionic villi endothelial cells)
[25–27] and to adult thymic epithelial cells [28]. This
very restricted tissue distribution of nonclassical HLA-G
gene expression in normal physiologic situations may
now be extended to normal human cornea. Phenotype
analysis of HLA-G expression disclosed no difference
between normal corneas and those presenting pseudopha-
kic bullous keratopathy or keratoconus. In such a study
at the phenotype level, no modulation of HLA-G protein
expression in pathologic corneas could attribute a role to
this protein in corneal disorders. Nevertheless, implica-
tion of HLA-G in ocular pathologies must not be ex-
cluded, in view of the fact that the distribution of
HLA-G polymorphisms has already been correlated with
such pathologies as preeclampsia [29].
The recent development of antibodies specific for the
HLA-G1 and HLA-G5 molecules allows their detection
in tissues that were found negative using previous mo-
lecular biology tools [30]. Finding HLA-G protein in
adult human cornea opens the possibility of an implica-
tion of HLA-G in eye immunity. Now that we have
demonstrated the presence of HLA-G in various corneal
structures, it would be interesting to understand their
role in the eye. The function of HLA-G in corneal tissue
must be further analyzed, especially considering ophthal-
mologists’ increased interest in the amniotic membrane
(a site of known HLA-G expression) to apply it on to the
ocular surface, as well as intracorneally, as a tissue-
engineered barrier able to protect against host immune
cell infiltration [31].
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